Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
600
Enrollment
OTHER
Sponsor class
Conditions
Obesity
Diabetes Type 2
Interventions
DRUG:
Semaglutide Pen Injector [Ozempic]
Sponsor
University of Maryland, Baltimore